The Strategy behind Galapagos' Expansion
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 77 (Table of Contents)
Published: 1 Nov-2006
DOI: 10.3833/pdr.v2006.i77.431 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
In little more than a year, the genomics-based drug discovery company Galapagos has transformed itself from a 'target discovery and validation company' into the Galapagos Group, an organisation with facilities across Europe, the US and Japan, which has the capability of taking drug targets through to clinical candidates...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS